Aerogen receives Ruban dHonneur award for global growth strategy Irish company Aerogen.

John Power, CEO of Aerogen stated ‘At a time when the concentrate for economic recovery is on promoting export led growth, we’re delighted to get a Ruban d’Honneur accolade. Aerogen has worked hard to determine a focused growth technique which has enabled us to expand our business into new marketplace areas such as drug delivery partnerships, alongside our primary product offerings. In fact, since our management buyout in 2008 we have quadrupled sales.’ Aerogen’s international growth strategy has helped the business to create and maintain a competitive benefit in the medication delivery and medical device sector.This award helps motivate the top students from typically underrepresented organizations to pursue professions in hematology research, stated ASH President Hal Broxmeyer, PhD. Since its introduction in 2004, the MMSAP has benefited both the recipients and the field of hematology as a whole. Related StoriesAmputation isn’t wound healingVISERA 4K UHD endoscopy system gives surgeons 4x resolutionFDA grants accelerated approval for Tagrisso to take care of individuals with advanced NSCLCFor an eight – to 12-week period, MMSAP individuals will work closely with their mentors on a hematology-related research project.